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Paget's Disease
Stephen M. Krane, MD*

fd. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13,1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents of the Proceedings can be found atthe back of
this issue.

What is the etiology of Paget's disease and can we cure it?
F.R. Singer and B.G. Mills (380)
Do calcitonins help Paget's disease of bone? O.L.M. Bijvoet (389)
Bisphosphonate treatment for Paget's disease of bone.
O.L.M. Bijvoet (389)
Mithramycin treatment of Paget's disease of bone exploration of c o m b i n e d therapies—particularly sodium etidronate (EHDP). W.G. Ryan (395)

Paget's disease of bone has been studied extensively by
many investigators interested in metabolic bone diseases. Yet Albright and Reifenstein (1) pointed out in
1948 that Paget's disease is not generalized and that normal bone can always be identified. The fact that Paget's
disease is localized to some but not to all bones was
offered as "strong evidence against its being a metabolic
or endocrine disorder." Whether or not Paget's disease
does belong in the category of metabolic bone diseases,
it has been possible to learn a great deal about bone
turnover in this disorder and successfully use therapeutic agents to help patients clinically.
We assume that the initial event in Paget's disease is a
focal resorption of existing normal bone (2). Histologically, this excessive resorption is shown by the increase
in the scalloped resorption spaces (Howship's lacunae)
filled with active osteoclasts that are larger and more
multinucleated. Even in the earliest biopsies of Pagetic
lesions, however, increased osteoblastic activity is evident with the deposition of lamellar or woven bone
adjacent to areas of resorption, frequently on opposite
surfaces. These events have been interpreted as indicating a marked increase in the " b i r t h rate" of the basic
multicellular units of bone (3). Although bone resorption and formation are both increased, the relative
increase in resorption is greater than that of normal
bone. The uninvolved non-Pagetic bone may not be
entirely normal and may show increased resorption and

osteoid surfaces. The latter changes have been interpreted as due to secondary hyperparathyroidism (3).
If resorption is the initial event in Paget's disease and the
increases in bone formation are coupled to increases in
resorption, t h e n it would follow that if one decreases the
resorption rate, the formation rateshould also decrease.
In fact, it has been possible to decrease bone resorption
in Paget's disease by using three different types of agents
(calcitonins, diphosphonates, and mithramycin). Indices
of bone formation decrease later than those of bone
resorption. Although each of these drugs reduces osteoclast function and possibly the generation of new osteoclasts f r o m precursor cells, the activity of the disease
eventually returns to pretreatment levels after therapy is
discontinued. The Pagetic lesion therefore is not cured.
Recent evidence has suggested that Paget's disease is due
to infection of osteoclasts or osteoclast precursors by a
virus possibly related to measles or respiratory syncytial
virus. F.R. Singer and B.G. Mills (pp. 380 ff.) presented the
evidence for viral infection of Pagetic cells and discussed
the problems in identifying possible agents. If a virus is
definitively identified, it will still be essential to prove that

• D e p a r t m e n t of M e d i c i n e , Harvard M e d i c a l School and Massachusetts General
Hospital, Boston.
Address reprint requests to Dr. Krane, D e p a r t m e n t of M e d i c i n e , Massachusetts
General Hospital, 32 Fruit Street, Boston, M A 02114.

227

Krane

TABLE
c l i n i c a l Problems in Patients with Paget's Disease of Bone
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

Pain over lesions
Deformities
Joint disease
Neural compression
Propensity to fracture
Vascular effects: high b o n e f l o w , high cardiac o u t p u t ,
" s t e a l " syndromes.
Disabling fatigue
Hypercalcemia and hypercalciuria
Hyperuricemia
Tumors: reparative granulomas, malignant neoplasms

Other features are responsive, particularly pain over
lesions demonstrable radiologically or by bone scan.

Fig.i
Radiograph of the pelvis and hips of a patient w i t h Paget's disease of
b o n e . The w h o l e right hemipelvis and proximal f e m u r is involved. The
right hip joint has the typical appearance of Pagetic coxopathy w i t h loss
of apparent j o i n t space over the entire articular circumference of the
femoral head and acetabular p r o t r u s i o n . In a d d i t i o n , there is a pathological fracture (arrow) of the right pubic ramus. These illustrate c o m m o n complications of Paget's disease.

this agent is the cause of the disease and not simply a
passenger. If the former is the case, Paget's disease can be
cured only if the putative virus is eliminated or if the
deleterious consequences ofsuch infection (altered proliferation and function of bone cells) are reversed.
At present, we must treat the clinical problems of Paget's
disease (Table). Although most patients are asymptomatic or have relatively little involvement, others must
be treated with calcitonin, diphosphonates (bisphosphonates) or mithramycin, or possibly combinations of
these drugs. Not all clinical problems are responsive to
drug therapy. For example, it is probable that joint disease such as Pagetic coxopathy, once developed, will not
be reversed by medical management but will eventually
require and respond to total hip replacement. However,

Certain aspects of the use of calcitonins were reviewed
by Nagant de Deauxchaisnes (pp. 384 ff.). He described
the success of calcitonins in improving the focal lesions
with apparent healing of the osteolytic disease and
replacement with mineralized bone. Bijvoet (pp. 389 ff.)
discussed the use of the bisphosphonates and emphasized their extraordinary potency in inhibiting bone
resorption. This has been demonstrated in numerous
careful studies with etidronate disodium and is reflected
in the normalization of the abnormally high urinary
hydroxyproline excretion. In Bijvoet's experience, use of
etidronate disodium results in clinical improvement in
most instances, although some individuals have a temporary increase in bone pain. Fractures were not a problem in his series. Osteolytic Pagetic lesions increased in
some individuals, as stressed by Nagant de Deuxchaisnes.
In contrast, APD (disodium [3-amino-1 hydroxypropylidene]-1, 1-bisphosphonate), the most potent of the
available bisphosphonates appears to arrest osteolytic
lesions and helps to fill in defects. Unfortunately, APD has
not been approved for use in most countries, including
the US. Experience with mithramycin was reviewed by
Ryan (pp. 395 ff.). Although this drug effectively reduces
abnormal chemical findings in Paget's disease and improves
symtoms and abnormal bone scans, it is potentially the
most toxic of available drugs and must be used with
caution. The long-term remissions that have occasionally
been observed after a brief course of therapy have provided impetus for study of further potential uses of
mithramycin alone or in combination with other agents.
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